1-(Naphthalen-1-yl)guanidine hydrochloride | 6967-90-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-(Naphthalen-1-yl)guanidine hydrochloride
• 英文别名: 2-naphthalen-1-ylguanidine;hydrochloride
• CAS: 6967-90-4
• 化学式: C11H12ClN3
• 分子量: 221.68
• InChiKey: ITPJCQQQTWMTHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.17
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.4
• 氢给体数：
  3
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  丙烯酸甲酯（MA） 、 1-(Naphthalen-1-yl)guanidine hydrochloride 、 sodium ethanolate 生成 2-amino-3-naphthalen-1-yl-4,5-dihydropyrimidin-6-one;hydrochloride
  参考文献：
  名称：

  WENDELIN, W.;RIEDL, R., MONATSH. CHEM., 1985, 116, N 2, 237-251

  摘要：

  DOI：

文献信息

• EP0517852A4
  申请人：——

  公开号：EP0517852A4

  公开（公告）日：1994-03-02
• TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of

  公开号：EP0517852A1

  公开（公告）日：1992-12-16
• N,N'-DI-1 NAPHTHYLGUANIDINE HCL (NAGH) AND N,N'-DI-P-NITROPHENYLGUANIDINE HCL (NAD) TREATMENT FOR STROKE AT DELAYED TIMEPOINTS
  申请人：Pennypacker Keith R.

  公开号：US20160151311A1

  公开（公告）日：2016-06-02

  A method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N′-di-1-Naphthylguanidine hydrochloride (NAGH); N,N′-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments.
• US9636311B2
  申请人：——

  公开号：US9636311B2

  公开（公告）日：2017-05-02
• [EN] TRI- AND TETRA-SUBSTITUTED GUANIDINES AND THEIR USE AS EXCITATORY AMINO ACID ANTAGONISTS
  申请人：STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALF SCIENCES UNIVERSITY

  公开号：WO1991012797A1

  公开（公告）日：1991-09-05

  (EN) Tri- and tetra-substituted guanidines which exhibit a high binding affinity to phencyclidine (PCP) receptors and, more preferably, low affinity to the brain sigma receptors. These guanidine derivatives act as non-competitive inhibitors of glutamate induced responses of the NMDA receptor by acting as blockers for the ion channel of the NMDA receptor-ion channel complex. These compounds thus exert neuroprotective activity and are useful in the therapeutic treatment of neuronal loss in hypoxia, hypoglycemia, brain or spinal cord ischemia, and brain or spinal cord trauma as well as being useful for the treatment of epilepsy, Alzheimer's disease, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, Down's Syndrome, Korsakoff's disease and other neurodegenerative disorders.(FR) L'invention concerne des guanidines tri et tetra substitués qui présentent une grande affinité de liaison aux récepteurs de phencyclidine (PCP) et, plus préférablement, une faible affinité aux récepteurs sigma du cerveau. Ces dérivés de guanidine agissent comme des inhibiteurs non compétitifs des réponses induites par le glutamate du récepteur NMDA en agissant comme bloqueurs du canal d'ion du complexe récepteur NMDA - canal d'ion. Ces composés excercent ainsi une activité neuroprotectrice et sont utiles dans le traitement thérapeutique de perte neuronale en hypoxie, hypoglycémie, ischémie du cerveau ou de la moelle épinière, et traumatisme du cerveau ou de la moelle épinière et sont également utiles pour le traitement de l'épilepsie, de la maladie d'Alzheimer, la sclérose latérale amyotrophique, la maladie de Parkinson, la maladie de Huntington, le syndrome de Down, la maladie de Korsakoff et d'autres troubles neurodégénératifs.